In a network meta-analysis of randomized trials in patients with MASH, the combination semaglutide + firsocostat ranked among the most effective regimens (SUCRA 62.43) for a ≥30% decline in MRI-PDFF at 24 weeks.
In plain wordsIn a pooled analysis of MASH trials, semaglutide combined with firsocostat ranked among the better treatments for lowering liver fat.
- Peptide
- Semaglutide
- Outcome
- Not applicableAt least 30% decline in MRI-PDFF at 24 weeks (SUCRA rank)
- Study
n: not reported in source
- Comparator
- Other pharmacological interventions in the network
- Analysis
- Secondary
- Outcome group
- Liver fat and liver function · Liver
Measurements
- SUCRA
- 62.43
- semaglutide + firsocostat, ≥30% MRI-PDFF decline at 24 weeks
Source sentences
At 24 weeks, efinopegdutide (SUCRA: 67.02), semaglutide + firsocostat (SUCRA: 62.43), and pegbelfermin (SUCRA: 61.68) were ranked the most effective interventions for achieving a ≥30% decline in MRI-PDFF.
1 context sentence(design, population, supporting numbers)
Of 1550 records, a total of 39 randomized controlled trials (3311 participants) met the inclusion criteria.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.